Across TCGA pan-cancer cohorts, TOMM7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TOMM7 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TOMM7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TOMM7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where TOMM7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.451	1.000	.016	25	view →
PDAC	OS	Median	All	0.781	0.370	.015	19	view →
UCEC	DFS	Median	II,III,IV	0.549	0.867	.046	4	view →
HNSC	OS	Median	II,III,IV	1.000	0.950	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TOMM7 tumor-vs-normal RNA expression · all TOMM7 data types